# Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

> **NCT04493853** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1012 (actual)

## Conditions studied

- Hormone-Sensitive Prostate Cancer

## Interventions

- **DRUG:** Capivasertib
- **OTHER:** Placebo
- **DRUG:** Abiraterone Acetate

## Key facts

- **NCT ID:** NCT04493853
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-13
- **Primary completion:** 2024-10-07
- **Final completion:** 2027-03-31
- **Target enrollment:** 1012 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493853, "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04493853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*